| pubmed-article:12364427 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12364427 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
| pubmed-article:12364427 | lifeskim:mentions | umls-concept:C0037663 | lld:lifeskim |
| pubmed-article:12364427 | lifeskim:mentions | umls-concept:C1521970 | lld:lifeskim |
| pubmed-article:12364427 | lifeskim:mentions | umls-concept:C1521827 | lld:lifeskim |
| pubmed-article:12364427 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:12364427 | lifeskim:mentions | umls-concept:C1709518 | lld:lifeskim |
| pubmed-article:12364427 | lifeskim:mentions | umls-concept:C0876109 | lld:lifeskim |
| pubmed-article:12364427 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:12364427 | pubmed:dateCreated | 2002-10-4 | lld:pubmed |
| pubmed-article:12364427 | pubmed:abstractText | A pharmacokinetic-pharmacodynamic study of a long-acting GH [Nutropin Depot; somatropin (rDNA origin) for injectable suspension] was performed in 25 patients with adult GH deficiency. Single doses of 0.25 mg/kg and 0.5 mg/kg, based on ideal body weight, were administered sc. After either dose, serum GH concentrations rose rapidly in both sexes. In men, the lower dose maintained serum IGF-I levels within 1 SD of the mean for age and sex for 14-17 d; the higher dose raised IGF-I levels 2 SD above the mean. In most women, all of whom were receiving oral estrogen, the lower dose did not normalize IGF-I levels; the higher dose maintained IGF-I near the mean for approximately 14 d. Increases in IGF binding protein-3 and acid-labile subunit levels were observed in both sexes; however, a sex-related difference was not obvious. Fasting glucose and insulin concentrations were transiently elevated in men receiving the higher dose. Patients tolerated the injections well. We concluded that a single injection of Nutropin Depot at these doses in patients with adult GH deficiency increased serum IGF-I to within normal limits for 14-17 d. Estrogen-treated women required approximately twice the dose needed in men to produce comparable IGF-I concentrations. | lld:pubmed |
| pubmed-article:12364427 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12364427 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12364427 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12364427 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:12364427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12364427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12364427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12364427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12364427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12364427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12364427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12364427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12364427 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12364427 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12364427 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:12364427 | pubmed:issn | 0021-972X | lld:pubmed |
| pubmed-article:12364427 | pubmed:author | pubmed-author:BenzigerD PDP | lld:pubmed |
| pubmed-article:12364427 | pubmed:author | pubmed-author:PhillipsL SLS | lld:pubmed |
| pubmed-article:12364427 | pubmed:author | pubmed-author:CookD MDM | lld:pubmed |
| pubmed-article:12364427 | pubmed:author | pubmed-author:DaleC RCR | lld:pubmed |
| pubmed-article:12364427 | pubmed:author | pubmed-author:HoffmanA RAR | lld:pubmed |
| pubmed-article:12364427 | pubmed:author | pubmed-author:PalH KHK | lld:pubmed |
| pubmed-article:12364427 | pubmed:author | pubmed-author:FielderP JPJ | lld:pubmed |
| pubmed-article:12364427 | pubmed:author | pubmed-author:VanceM LML | lld:pubmed |
| pubmed-article:12364427 | pubmed:author | pubmed-author:BlethenS LSL | lld:pubmed |
| pubmed-article:12364427 | pubmed:author | pubmed-author:AttieK MKM | lld:pubmed |
| pubmed-article:12364427 | pubmed:author | pubmed-author:ReimannJ DJD | lld:pubmed |
| pubmed-article:12364427 | pubmed:author | pubmed-author:BillerB M KBM | lld:pubmed |
| pubmed-article:12364427 | pubmed:author | pubmed-author:IlleperumaAA | lld:pubmed |
| pubmed-article:12364427 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12364427 | pubmed:volume | 87 | lld:pubmed |
| pubmed-article:12364427 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12364427 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12364427 | pubmed:pagination | 4508-14 | lld:pubmed |
| pubmed-article:12364427 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:12364427 | pubmed:meshHeading | pubmed-meshheading:12364427... | lld:pubmed |
| pubmed-article:12364427 | pubmed:meshHeading | pubmed-meshheading:12364427... | lld:pubmed |
| pubmed-article:12364427 | pubmed:meshHeading | pubmed-meshheading:12364427... | lld:pubmed |
| pubmed-article:12364427 | pubmed:meshHeading | pubmed-meshheading:12364427... | lld:pubmed |
| pubmed-article:12364427 | pubmed:meshHeading | pubmed-meshheading:12364427... | lld:pubmed |
| pubmed-article:12364427 | pubmed:meshHeading | pubmed-meshheading:12364427... | lld:pubmed |
| pubmed-article:12364427 | pubmed:meshHeading | pubmed-meshheading:12364427... | lld:pubmed |
| pubmed-article:12364427 | pubmed:meshHeading | pubmed-meshheading:12364427... | lld:pubmed |
| pubmed-article:12364427 | pubmed:meshHeading | pubmed-meshheading:12364427... | lld:pubmed |
| pubmed-article:12364427 | pubmed:meshHeading | pubmed-meshheading:12364427... | lld:pubmed |
| pubmed-article:12364427 | pubmed:meshHeading | pubmed-meshheading:12364427... | lld:pubmed |
| pubmed-article:12364427 | pubmed:meshHeading | pubmed-meshheading:12364427... | lld:pubmed |
| pubmed-article:12364427 | pubmed:meshHeading | pubmed-meshheading:12364427... | lld:pubmed |
| pubmed-article:12364427 | pubmed:meshHeading | pubmed-meshheading:12364427... | lld:pubmed |
| pubmed-article:12364427 | pubmed:meshHeading | pubmed-meshheading:12364427... | lld:pubmed |
| pubmed-article:12364427 | pubmed:meshHeading | pubmed-meshheading:12364427... | lld:pubmed |
| pubmed-article:12364427 | pubmed:meshHeading | pubmed-meshheading:12364427... | lld:pubmed |
| pubmed-article:12364427 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12364427 | pubmed:articleTitle | The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults. | lld:pubmed |
| pubmed-article:12364427 | pubmed:affiliation | Department of Medicine, Oregon Health Sciences University, Portland, Oregon 97201, USA. cookd@ohsu.edu | lld:pubmed |
| pubmed-article:12364427 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12364427 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:12364427 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12364427 | lld:pubmed |
